Nocturnal polyuria, treatment with desmopressin

Česká verzia

Authors: R. Zachoval ^1,4; J. Krhut ²; O. Šottner ³; T. Hanuš ⁴; A. Martan ⁵ ; L. Horčička ⁶; J. Feyereisl ⁷; M. Halaška ³; K. Švabík ⁵; L. Krofta ⁷
Authors place of work: Urologické oddělení, Thomayerova nemocnice, Praha ¹; Urologické oddělení Fakultní nemocnice, Ostrava ²; Gynekologicko-porodnická klinika Nemocnice na Bulovce a 1. LF UK, Praha, prof. MUDr. M. Halaška, DrSc. ³; Urologická klinika VFN a 1. LF UK, Praha, přednosta prof. MUDr. T. Hanuš, DrSc. ⁴; Gynekologicko-porodnická klinika VFN a 1. LF UK, Praha, přednosta prof. MUDr. A. Martan, DrSc. ⁵; Nestátní zdravotnické zařízení GONA, s. r. o., gynekologie, Praha ⁶; Ústav pro péči o matku a dítě, Praha, ředitel doc. MUDr. J. Feyereisl, CSc. ⁷
Published in the journal: Ceska Gynekol 2013; 78(4): 385-389

Summary

Nonpharmacologic and especially pharmacologic treatment options are available for nocturnal polyuria.

Desmopressin represents the basis of pharmacologic treatment. Desmopressin acetate is a synthetic analogue of arginine vasopressin with high affinity to V2 receptors with antidiuretic effect. It is the only medicament currently registered for antidiuretic treatment. Desmopressin has not any relevant affinity to V1 receptors, and therefore there is no hypertensive effect in contrary to natural vasopressin.

Desmopressin use before a bedtime leads to reduced production of urine during a sleep, therefore time between desires to void is prolonged and number of nocturia is reduced. Clinical effect, in a meaning of reduced urine production and increased osmolality of urine, lasts approximately 8-12 hours. In the treatment of nocturnal polyuria desmopressin is used orally one hour before a bedtime. It is essential to titrate an ideal dose, the initial dose is 60 µg of MELT formula (fast melting oral formulation) and it can be increased according to the clinical effect up to the maximal recommended daily dose 240 µg. Patients treated with desmopressin should cut down a fluid intake 1 hour before and 8 hours after the use of desmopressin.

Total number of adverse events connected withdesmopressin treatment in clinical studies was higher compared to placebo but the side effects were mostly mild. The most common adverse events were headaches, nausea, diarrhoea, abdominal pain, dry mouth and hyponatremia both in the short-term and long-term clinical trials. Hyponatremia was observed mainly in patients over 65 year of age. Therefore treatment with desmopressin should not be commended in patients over 65 year of age without close monitoring of the natrium level in serum and all patients should be informed about the first symptoms of hyponatremia – headache, nausea and insomnia.

According to Evidence Based Medicine, the level of evidence for treatment of nocturnal polyuria with desmopressin is 1b and the grade of recommendation for treatment is A.

Keywords:
nocturnal polyuria – treatment – desmopressin

Zdroje

1. Asplund, R., Sundberg, B., Bengtsson, P. Desmopressin for the treatment of nocturnal polyuria in the elderly: a dose titration study. Br J Urol, 1998, 82, 5, p. 642–646.

2. Asplund, R., Sundberg, B., Bengtsson, P. Oral desmopressin for nocturnal polyuria in elderly subjects: a double-blind, placebo-controlled randomized exploratory study. BJU Int, 1999, 83, 7, p. 591–595.

3. Bae, JH., Oh, MM., Shim, KS., et al. The effects of long-term administraion of oral desmopressin on the baseline secretion of antidiuretic hormone and serum sodium concentration for the treatment of nocturia: a circadian study. J Urol, 2007, 178, 1, p. 200–203.

4. Brownstein, MJ. Vasopressin/oxytocin receptor family. In Lennarz, WJ., Lane, MD. Encyclopedia of biological chemistry, Four-Volume Set, 2004, p. 114–116.

5. Cannon, A., Carter, PG., McConnell, AA., et al. Desmopressin in the treatment of nocturnal polyuria in the male. BJU Int, 1999, 84, 20, p. 20–24.

6. Cammak, R. Oxford dictionary of biochemistry and molecular biology. Revised ed. Oxford: Oxford University Press, 2006, p. 634.

7. Chancellor, MB., Atan, A., Rivas, DA. et al. Beneficial effect of intranasal desmopressin for men with benign prostatic hyperplasia and nocturia: preliminary results. Tech Urol, 1999, 5, 4, p. 191–194.

8. Fjellestad-Paulsen, A. Hoglund, P., Lundin, S., et al. Pharmacokinetics of 1-deamino-8-D-arginine vasopressin after various routes of administration in healthy volunteers. Clin Endocrinol, 1993, 38, 2, p. 177–182.

9. Hvistendahl, GM., Riis, A., Norgaard, JP., et al. The pharmacokinetics of 400 g of oraldesmopressin in elderly patients with nocturia, and the correlation between the absorption of desmopressin and clinical effect. BJU Int, 2005, 95, 6, p. 804–809.

10. Kuo, HC. Efficacy of desmopressin in treatment of refraktory nocturia in patients older than 65 years. Urology, 2002, 59, 6, p. 485–489.

11. Lose, G., Mattiasson, A., Walter, S., et al. Clinical experiences with desmopressin for long-term treatment of nocturia. J Urol, 2004, 172, 3, p. 1021–1025.

12. Mattiasson, A., Abrams, P., van Kerrebroeck, P., et al. Efficacy of desmopressin in the treatment of nocturia: a double-blind, placebo-controlled study in men. BJU Int, 2002, 89, 9, p. 855–862.

13. Rembratt, A. Graugaard-Jensen, C., Senderovitz, T., et al. Pharmacokinetics and pharmacodynamics od desmopressin administered orally versus intravenously at daytime versus night-time in healthy men aged 55-70 years. Eur J Clin Pharmacol, 2004, 60, 6, p. 397–402.

14. Rembratt, A., Norgaard, JP., Andersson, KE. Desmopressin in elderly patients with nocturia: short-term sagety and effects on urine output, sleep and voiding patterns. BJU Int, 2003, 9, 17, p. 642–646.

15. Rembratt, A., Riis, A., Norgaard, JP. Desmopressin treatment in nocturia: an analysis of risk factors for hyponatremia. Neurourol Urodyn, 2006, 25, 2, p. 105–109.

16. Smith, CUM. Elements of molecular neurobiology. 3. ed. Chichester: John Wiley & Sons, 2002, p. 185.

17. van Kerrebroeck, P., Rezapour, M., Cortesse, A., et al. Desmopressin in the treatment of nocturia: a double blind placebo-controlled study. Eur Urol, 2007, 52, 1, p. 221–229.

18. Weatherall, M. The risk of hyponatremia in older adults using desmopressin for nocturia: a systematic review and meta-analysis. Neurourol Urodyn, 2004, 23, 4, p. 302–305.